OncoBayes avanza con OB-001 para abordar la resistencia a ADC y la penetración cerebral de TKI

OncoBayes, a privately held clinical-stage pharmaceutical company, announced successful completion of preclinical studies of OB-001. The company said the results demonstrate the product’s potential to address two significant unmet needs in oncology; the excerpt provides no study data or further details.